Michael Mullowney

Mr. Michael Mullowney


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2019 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
JNJorge C. Navarro-Muñoz
Jorge C. Navarro-Muñoz
Nelly Selem MojicaNelly Selem Mojica
Nelly Selem Mojica
MMMichael Mullowney
Michael Mullowney
SKSatria A. Kautsar
Satria A. Kautsar
JTJames H. Tryon
James H. Tryon
MMMarnix H. Medema
Marnix H. Medema

11 September 2023 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
MMMichael Mullowney
Michael Mullowney
KDKatherine Duncan
Katherine Duncan
SESomayah Elsayed
Somayah Elsayed
NGNeha Garg
Neha Garg
Justin Van der HooftJustin Van der Hooft
Justin Van der Hooft
MMMarnix H. Medema
Marnix H. Medema

15 February 2021 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
MSMichelle A. Schorn
Michelle A. Schorn
SVStefan Verhoeven
Stefan Verhoeven
LRLars Ridder
Lars Ridder
FHFlorian Huber
Florian Huber
DADeepa D. Acharya
Deepa D. Acharya
Justin Van der HooftJustin Van der Hooft
Justin Van der Hooft
Genomics and metabolomics are widely used to explore specialized metabolite diversity. The Paired Omics Data Platform is a community initiative to systematically document links between metabolome and (meta)genome data, aiding identification of natural product biosynthetic origins and metabolite structures.

19 June 2018 in Natural Product Reports
Verified
Journal Article
Closed access
PDF file
MMMichael Mullowney
Michael Mullowney
RMRyan A. McClure
Ryan A. McClure
MRMatthew T. Robey
Matthew T. Robey
NKNeil Kelleher
Neil Kelleher
RTRegan J. Thomson
Regan J. Thomson
Thioester reductases arm natural products, such as the peptide aldehydes and the anti-cancer drug Yondelis, with unique structures and bioactivity.

4 January 2024 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
ALAlexander S. Little
Alexander S. Little
IYIsaac T. Younker
Isaac T. Younker
MSMatthew S. Schechter
Matthew S. Schechter
PBPaola Nol Bernardino
Paola Nol Bernardino
RMRaphaël Méheust
Raphaël Méheust
SLSamuel H. Light
Samuel H. Light

3 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
MSMatthew R. Stutz
Matthew R. Stutz
NDNicholas P. Dylla
Nicholas P. Dylla
SPSteven D. Pearson
Steven D. Pearson
PLPaola Lecompte-Osorio
Paola Lecompte-Osorio
RNRavi Nayak
Ravi Nayak
BPBhakti K. Patel
Bhakti K. Patel
Respiratory failure and mortality from COVID-19 result from virus- and inflammation-induced lung tissue damage. The intestinal microbiome and associated metabolites are implicated in immune responses to respiratory viral infections, however their impact on progression of severe COVID-19 remains unclear. We prospectively enrolled 71 patients with COVID-19 associated critical illness, collected fecal specimens within 3 days of medical intensive care unit admission, defined microbiome compositions by shotgun metagenomic sequencing, and quantified microbiota-derived metabolites (NCT #04552834). Of the 71 patients, 39 survived and 32 died. Mortality was associated with increased representation of Proteobacteria in the fecal microbiota and decreased concentrations of fecal secondary bile acids and desaminotyrosine (DAT). A microbiome metabolic profile (MMP) that accounts for fecal secondary bile acids and desaminotyrosine concentrations was independently associated with progression of respiratory failure leading to mechanical ventilation. Our findings demonstrate that fecal microbiota composition and microbiota-derived metabolite concentrations can predict the trajectory of respiratory function and death in patients with severe SARS-Cov-2 infection and suggest that the gut-lung axis plays an important role in the recovery from COVID-19.